Utilidad del porcentaje de antígeno prostático específico libre en comparación al antígeno prostático especifico total para detección de cáncer prostático

Hugo  Alpaca-Salvador; Hugo Eduardo  Fernández Cosavalente

doi:10.35434/rcmhnaaa.2023.163.1949

Authors

Hugo Alpaca-Salvador Escuela Profesional de Medicina Humana, Universidad Nacional del Santa, Nuevo Chimbote, Perú; Servicio de Patología Clínica y Anatomía Patológica, Hospital III EsSalud Chimbote, Chimbote, Perú
Hugo Eduardo Fernández Cosavalente Facultad de Medicina, Universidad Nacional de Trujillo, Trujillo, Perú

DOI:

https://doi.org/10.35434/rcmhnaaa.2023.163.1949

Keywords:

Prostatic Neoplasms, prostate-specific antigen, early detection of cancer, sensitivity, specificity

Abstract

Background: The determination of the specific prostate antigen is widely used in the early detection of prostate cancer; however, a limitation has been its relative lack of specificity where the quantification of some isoforms as their free fraction could improve discrimination with benign prostate disease. The objective of the study was to compare the diagnostic performance of the percentage of free prostate specific antigen and the total prostate specific antigen for the detection of prostate cancer. Material and Methods: A retrospective investigation of validity and comparison of diagnostic tests was carried out with a consecutive sample of 56 cases of prostatic adenocarcinoma and 161 controls with benign prostatic hyperplasia treated at Hospital III EsSalud Chimbote from November 2015 to February 2020. Results: The percentage of free prostate specific antigen presented an area under the curve (AUC) of 0.82 (95% CI: 0.75 – 0.89), an optimal cut-off of 20.0%, sensitivity of 95.0 %, specificity of 35.0% and diagnostic accuracy of 50.2%; compared to total prostate specific antigen, which obtained an AUC of 0.76 (95% CI: 0.69-0.83), sensitivity of 96.4%, specificity of 24.2%, and diagnostic accuracy of 42.86%. Conclusions: The percentage of free prostate specific antigen presented a moderate and higher diagnostic performance than the total prostate specific antigen for the detection of prostate cancer and could reduce the proportion of unnecessary biopsies by 35.0%.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Hugo Alpaca-Salvador , Escuela Profesional de Medicina Humana, Universidad Nacional del Santa, Nuevo Chimbote, Perú; Servicio de Patología Clínica y Anatomía Patológica, Hospital III EsSalud Chimbote, Chimbote, Perú

1. Médico Patólogo Clínico, magister en Bioquímica Clínica

Hugo Eduardo Fernández Cosavalente, Facultad de Medicina, Universidad Nacional de Trujillo, Trujillo, Perú

1. Médico Pediatra, doctor en Medicina.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-49. doi: 10.3322/caac.21660

Tourinho-Barbosa RR, Pompeo ACL, Glina S. Prostate cancer in Brazil and Latin America: epidemiology and screening. International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology. 2016;42(6):1081. doi: 10.1590/S1677-5538.IBJU.2015.0690

Ramos W, Guerrero N. Análisis de la situación del cáncer en el Perú, 2018 [Internet]. Lima: Ministerio de Salud: Centro Nacional de Epidemiología, Prevención y Control de Enfermedades Ministerio de Salud; 2020 [citado el 12 de diciembre del 2020]. Disponible en: https://www.dge.gob.pe/epipublic/uploads/asis/asis_2020.pdf

Prieto J, Ramón J. Balcells. La clínica y el laboratorio. 23rd ed. Navarra: Elsevier; 2019.

Cuentas-Jara M, Goicochea-Lugo S, Delgado-Flores CJ, Romero-Robles MA, Taype-Rondan A, Cordier-Mariaca A, et al. Guía de práctica clínica para el tamizaje, diagnóstico y tratamiento inicial de cáncer de próstata localizado y localmente avanzado en el Seguro Social del Perú (EsSalud). Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo.2021;14(2):195-206. doi:10.35434/rcmhnaaa.2021.142.1063.

Ruiz L, Pérez M, Cruz B, et al. Actualización sobre cáncer de próstata. CCM [Internet]. 2017 [citado el 03 de enero del 2020];21(3):876-887.Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1560-43812017000300021

Filella X, Foj L. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. International Journal of Molecular Sciences [Internet] 2016;17(11):1784. Available from: http://dx.doi.org/10.3390/ijms1711178

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. Guía de la EAU sobre el cáncer de próstata: Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado. Actas Urológicas Españolas. 2011;35(9):501-14. doi:10.4321/S0210-48062011000900001

Filella X, Albaladejo MD, Allué JA, Castaño MA, Morell-Garcia D, Ruiz MÀ, et al. Prostate cancer screening: guidelines review and laboratory issues. Clinical Chemistry and Laboratory Medicine (CCLM). 2019;57(10):1474-87. doi: 10.1515/cclm-2018-1252

Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. Internal Medicine Journal. 2014;44(5):433-40. doi: 10.1111/imj.12407.

Sagué L, Priaño S, Doimeadiós Z. Papel del antígeno prostático específico en el cribado masivo o individual. CCM [Internet]. 2019 [Citado el 03 de enero del 2020];23(1):210-221. Disponible: scielo.sld.cu/pdf/ccm/v23n1/1560-4381-ccm-23-01-210.pdf.

Munteanu VC, Munteanu RA, Gulei D, Schitcu VH, Petrut B, Neagoe IB, et al. PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer. Diagnostics. 2020;10(10).806. doi: 10.3390/diagnostics10100806.

Terreros M, Valdés YC, Gonzáles LB, Mercader OA, Romero S. Prostate-specific antigen levels in patients with risk factors for prostate carcinoma disorders. Jornal Brasileiro de Patologia e Medicina Laboratorial .2020;56:1-6. doi:10.5935/1676-2444.

Brenes F, Martínez-Berganza L. Manejo en el seguimiento del varón con hiperplasia benigna de próstata: Síntomas del tracto urinario inferior y antígeno prostático específico. Madrid: IMC;2018. Disponible en: https://semergen.es/files/docs/grupos/urologia/Modulo2%20HBP%20y%20PSA.pdf

Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008; 102:1400-6. doi: 10.1111/j.1464-410X.2008.07817.x.

Laguna MP, Wondergem N, Wink MH, Wijkstra H, de la Rosette J. Avances en el diagnóstico ecográfico del cáncer de próstata. Arch Esp Urol.2006; 59 (10):965-976

De Torres I. Factores pronósticos y predictivos del carcinoma de próstata. Actas Urol Esp [Internet]. 2007 [citado el 03 de enero del 2020];31(9):1025-1044. Disponible en: scielo.isciii.es/pdf/aue/v31n9/v31n9a10.pdf.

Welch HG, Schwartz LM, and Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005; 97:1132-7. doi: 10.1093/jnci/dji205.

Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower. JAMA. 2005;294(1):66-70. doi: 10.1001/jama.294.1.66.

Virginia A. Moyer. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med.2012;157:120-134. doi: 10.7326/0003-4819-157-2-201207170-00459

Obuchowsky N. Sample size calculations in studies of test accuracy. Stat Methods Med Res 1998; 7: 371-92. doi: 10.1177/096228029800700405.

Loayza Palomino C. Exactitud global de las concentraciones plasmáticas de antígeno prostático específico en el diagnóstico de cáncer de próstata-Hospital Regional Docente de Trujillo, octubre del 2009-junio 2010. [Tesis doctoral]. Trujillo: Universidad Nacional de Trujillo; 2011.Disponible en:http://dspace.unitru.edu.pe/handle/UNITRU/5419

Cárdenas L, Chalco-Moreno P, Berrocal-Salcedo J. Valor predictivo del PSA libre/total en cáncer de próstata en pacientes del hospital regional de Ica. Revista Médica Panacea. 2019;6(1):12-16. doi:10.35563/rmp.v6i1.178.

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen–Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;319(18):1914-31. doi: 10.1001/jama.2018.3712.

Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018; 5 (362): k3519. doi: 10.1136/bmj.k3519.

Wang Y, Sun G, Pan JG, Guo ZJ, Li T. Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis. Prostate Cancer Prostatic Diseases. 2006;9(4):374-8. doi: 10.1038/sj.pcan.4500906.

Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial. JAMA. 1998;279(19):1542-7. doi: 10.1001/jama.279.19.1542.

Ortiz J, Almoguer E. La eficiencia del índice de PSA libre en el diagnóstico del cáncer de próstata. Anales de la Facultad de Medicina. 2015;76(1):27-32. doi:10.15381/anales.v76i1.11072.

Bruzzese D, Mazzarella C, Ferro M, Perdonà S, Chiodini P, Perruolo G, et al. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with “gray” prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Translational Research. 2014;164(6):444-51. doi: 10.1016/j.trsl.2014.06.006.

Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS; Free PSA Study Group. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006;67(4):762-768. doi:10.1016/j.urology.2005.10.052

Roddam A, Duffy M, Hamdy F, et al. Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-Analysis, European Urology .2005 ;48(3):386-399. doi: 10.1016/j.eururo.2005.04.015.

Escobar M, Escobar C, Salvatierra P, Ruiz A, Villalobos T, Karlsruhen G, Sagredo A, Ortiz P. Utilidad del APE libre en el diagnóstico de cáncer de próstata. Revista Chilena de Urología [Internet]. 2014[citado 19 de febrero de 2023] ;79(2): 34-37. Disponible en: https://revistasacademicas.cl/schu/Articulos/Articulo/2458.

Gordillo Castro J. Eficacia del porcentaje de antígeno prostático específico libre en el diagnóstico de neoplasia prostática en el Hospital Nacional Luis N. Sáenz,2015-2018. [Tesis de pregrado]. Lima: Universidad Privada San Juan Bautista; 2019.Disponible en: http://repositorio.upsjb.edu.pe/handle/upsjb/2230

Altman DG, Bland JM. Diagnostic tests 1: Sensitivity and specificity. BMJ 1994; 308(6943): 1552. doi: 10.1136/bmj.308.6943.1552.